1. Home
  2. LGND vs DKL Comparison

LGND vs DKL Comparison

Compare LGND & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • DKL
  • Stock Information
  • Founded
  • LGND 1987
  • DKL 2012
  • Country
  • LGND United States
  • DKL United States
  • Employees
  • LGND 68
  • DKL N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • DKL Natural Gas Distribution
  • Sector
  • LGND Health Care
  • DKL Energy
  • Exchange
  • LGND Nasdaq
  • DKL Nasdaq
  • Market Cap
  • LGND 2.2B
  • DKL 2.3B
  • IPO Year
  • LGND 1992
  • DKL N/A
  • Fundamental
  • Price
  • LGND $139.02
  • DKL $44.21
  • Analyst Decision
  • LGND Strong Buy
  • DKL Buy
  • Analyst Count
  • LGND 8
  • DKL 4
  • Target Price
  • LGND $144.71
  • DKL $44.25
  • AVG Volume (30 Days)
  • LGND 139.7K
  • DKL 71.1K
  • Earning Date
  • LGND 08-05-2025
  • DKL 08-05-2025
  • Dividend Yield
  • LGND N/A
  • DKL 10.07%
  • EPS Growth
  • LGND N/A
  • DKL 7.97
  • EPS
  • LGND N/A
  • DKL 2.98
  • Revenue
  • LGND $181,488,000.00
  • DKL $938,491,000.00
  • Revenue This Year
  • LGND $18.41
  • DKL $21.09
  • Revenue Next Year
  • LGND $18.87
  • DKL N/A
  • P/E Ratio
  • LGND N/A
  • DKL $14.79
  • Revenue Growth
  • LGND 53.40
  • DKL N/A
  • 52 Week Low
  • LGND $81.74
  • DKL $34.59
  • 52 Week High
  • LGND $129.90
  • DKL $45.71
  • Technical
  • Relative Strength Index (RSI)
  • LGND 75.81
  • DKL 61.00
  • Support Level
  • LGND $120.68
  • DKL $43.63
  • Resistance Level
  • LGND $126.24
  • DKL $44.64
  • Average True Range (ATR)
  • LGND 4.48
  • DKL 0.76
  • MACD
  • LGND 1.87
  • DKL -0.03
  • Stochastic Oscillator
  • LGND 96.06
  • DKL 85.71

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

Share on Social Networks: